Overview: Alpha-1-Antitrypsin Phenotype TestIntroduction: The Alpha-1-Antitrypsin Phenotype Test identifies genetic variants of alpha-1-antitrypsin (AAT) to diagnose deficiency, which can lead to lung or liver diseases causing breathing difficulties or jaundice. Following 2023 ATS guidelines, it uses an immunoassay to detect AAT variants, aiding in genetic screening. This test is critical for guiding treatment, lifestyle changes, and improving outcomes in immunology, particularly for patients with respiratory or hepatic symptoms.
Other Names: AAT Phenotype Assay, Alpha-1-Antitrypsin Genotyping.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: AAT deficiency was identified in the 1960s. Phenotyping assays emerged in the 1980s, and by the 2000s, genetic testing improved detection of AAT variants like Pi
Z and PiS.
Purpose: Diagnoses AAT deficiency, guides treatment, and monitors disease risk in patients with symptoms like breathing difficulties or jaundice.
Test Parameters: 1. Alpha-1-Antitrypsin Phenotype
Pretest Condition: No fasting required. Collect serum or plasma at any time. Report symptoms like shortness of breath, jaundice, or family history of AAT deficiency.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document respiratory or liver symptoms, smoking history, or family history of AAT deficiency. Include current medications, especially augmentation therapy.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for genetic counseling or treatment.
Procedural Considerations: Uses an immunoassay (e.g., isoelectric focusing) to identify AAT phenotypes. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Hemolysis or improper storage can degrade samples. Rare AAT variants may require genetic sequencing for confirmation.
Clinical Significance: Abnormal phenotypes (e.g., Pi
ZZ) confirm AAT deficiency, prompting augmentation therapy or lifestyle changes. Normal phenotypes may require quantitative AAT testing.Specialist Consultation
: Consult a pulmonologist or hepatologist for result interpretation. Genetic counseling is advised for affected families.Additional Supporting Tests
: AAT quantitative test, liver function tests, or genetic sequencing to confirm AAT deficiency or assess organ damage.Test Limitations
: Rare variants may be missed without genetic sequencing. Environmental factors like smoking may exacerbate symptoms, requiring clinical correlation.References: ATS/ERS AAT Deficiency Guidelines, 2023; American Journal of Respiratory and Critical Care Medicine, Sandhaus RA, 2022.
